Hjem › Leverkreft (hepatocellulært karcinom) › Texas
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Texas
50 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i Texas.
Byer i Texas
Offisiell studietekst (engelsk)
A Study of ZW251 in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- og 2 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06726161National Liver Cancer Screening Trial
- UT Southwestern Medical Center and Parkland Hospital, Dallas
- Baylor College of Medicine, Houston
RekruttererFase 4
Alder 18 til 85 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06427941Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
- M D Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT04380545Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- St. David's Medical Center, Austin
RekruttererObservasjonsstudie
Alder 22 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Amarillo
- Research Site, Austin
- Research Site, Houston
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06921785THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07446257Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 27. aug. 2026 · NCT06582017Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07689175Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 24. aug. 2026 · NCT06084481FOG-001 in Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05919264First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. aug. 2026 · NCT06795022A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- og 8 flere
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT05208762Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- M D Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jul. 2026 · NCT05092373Multi-analyte Blood Test Clinical Trial
- South Texas Research Institute, Edinburg
- Texas Gastro Research, El Paso
- Impact Research Institute, Waco
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jul. 2026 · NCT05199259CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
- University of Texas Southwestern Medical Center, Dallas
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT06184152A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
- Clinical Trial Site, San Antonio
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 17. jun. 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 17. jun. 2026 · NCT05486572A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jun. 2026 · NCT07116486A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 1
Alder 16 og eldre · Alle kjønn · Oppdatert 2. jun. 2026 · NCT07197554Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
- M D Anderson Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. mai 2026 · NCT04982653High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- M D Anderson Cancer Center, Houston
Rekrutterer
Alder 19 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT05053555DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA13-0, Anderson
- USA12-0, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Harold C. Simmons Comprehensive Cancer Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- DHR Health Institute for Research and Development, McAllen
- og 1 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. apr. 2026 · NCT05440708Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
- M D Anderson Cancer Center, Houston
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alle aldre · Alle kjønn · Oppdatert 15. apr. 2026 · NCT05143619A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. apr. 2026 · NCT06362369Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. apr. 2026 · NCT05733598Evaluation of Resection Techniques for Pancreatic Tumors
- Methodist Dallas Medical Center, Dallas
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 20. mar. 2026 · NCT05128890Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Oncology Consultants, Houston
RekruttererFase 1
Alder 18 til 65 · Alle kjønn · Oppdatert 16. mar. 2026 · NCT07176650Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. feb. 2026 · NCT06789848Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Baylor College of Medicine, Houston
RekruttererFase 2
Alder 0 til 30 · Alle kjønn · Oppdatert 24. feb. 2026 · NCT04134559Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.